FUJIFILM Diosynth Biotechnologies Expands Partnership with argenx for Efgartigimod Manufacturing

FUJIFILM Diosynth Biotechnologies and argenx have announced an extension of their partnership to include drug product and finished goods services for efgartigimod, a monoclonal antibody fragment addressing severe autoimmune diseases. This expanded collaboration builds upon their initial agreement for drug substance manufacturing, signifying a deepening commitment to advancing therapeutic solutions. Efgartigimod, already approved for generalized myasthenia gravis treatment in the United States and Europe, is now undergoing evaluation for other severe autoimmune conditions associated with disease-causing immunoglobulin G autoantibodies. The partnership's expansion underscores FUJIFILM Diosynth Biotechnologies' dedication to supporting argenx in delivering innovative therapies for unmet medical needs. Kenneth Bilenberg, Executive Vice President at FUJIFILM Diosynth Biotechnologies, expressed enthusiasm for this continued collaboration, stressing the importance of trust and partnership in driving impactful medical advancements.